- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Cosmos Rx, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis
- Interventions
- Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis Interstitial Lung Disease
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Radiation Fibrosis
- Interventions
- pirfenidone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Sclerosis
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Lebrikizumab, Pirfenidone, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
- Conditions
- NSCLC Stage IV, NSCLC, Recurrent
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Kansas City, Kansas
- Conditions
- Diabetes Mellitus, Diabetic Nephropathy
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Sharma, Kumar, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
- Interventions
- AP01, Placebo
- Drug · Other
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Long COVID
- Interventions
- Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- Douglas D. Fraser
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Neurofibromatosis 1, Neurofibroma, Plexiform
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone, Untreated Cohort
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Plymouth, Pennsylvania
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
- Interventions
- Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Covid19, Post-acute COVID-19 Respiratory Disease
- Interventions
- LYT-100, Placebo
- Drug · Other
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Deupirfenidone, Pirfenidone (PFD)
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Palm Spring, California • Redding, California • North Dartmouth, Massachusetts + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Vismodegib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 14
- States / cities
- La Jolla, California • Orlando, Florida • Elk Grove, Illinois + 11 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Retrospective observational study- no intervention to occur.
- Other
- Lead sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 1015550, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more
- Conditions
- Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- William Gahl, M.D.
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BBT-877, Placebo
- Drug
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
- Conditions
- Bronchiolitis Obliterans, Graft Vs Host Disease
- Interventions
- Pirfenidone 267 MG [Esbriet]
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California